Healthcare Global Enterprises showcases robust revenue expansion, as seen in its compounded sales growth. The quarterly sales also display a consistent rise, from ₹364.63 Cr in Mar 2022 to ₹585.16 Cr in Mar 2025. However, profit growth has shown volatility. Recent quarterly results indicate fluctuations in net profit, which impacts overall profitability. The OPM% exhibits variability, ranging from 17.32% in Mar 2022 to 18.05% in Mar 2025, indicating operational efficiency variations. This combination of strong sales growth but inconsistent profit trends signals the need for strategic adjustments to stabilize and enhance profitability.

The capital efficiency and returns for Healthcare Global Enterprises present a mixed scenario. The ROCE% has improved, with the latest value at 9% in Mar 2025. This indicates an improvement in the productivity of capital employed. However, the ROE% remains low at 5% in the last year, suggesting that shareholder funds are not generating high returns. The negative Cash Conversion Cycle indicates efficient working capital management.

| Metric | 2014–2016 | 2017–2019 | 2020–2022 | 2023 | 2024 | 2025 | |---------------------------|-----------|-----------|------|------|------| | ROCE (%) | 4.7 | 5.3 | 1.7 | 8.0 | 9.0 | 9.0 |

The financial health of Healthcare Global Enterprises is concerning due to increasing debt levels. Borrowings have risen significantly, from ₹292 Cr in Mar 2014 to ₹1,837 Cr in Mar 2025. The Debt/Equity ratio reflects this increasing leverage. Interest Coverage Ratio has fluctuated due to variations in operating profit and rising interest expenses. The company has not been paying dividends.

| Metric | 2014–2016 | 2017–2019 | 2020–2022 | 2023 | 2024 | 2025 | |---------------------------|-----------|-----------|------|------|------| | Borrowings (₹Cr) | 321.7 | 514.0 | 1079.7 | 901 | 1274 | 1837 | | Interest Coverage Ratio | -0.7 | 0.2 | -0.6 | -0.6 | -0.4 | -0.6 |

The shareholding pattern of Healthcare Global Enterprises indicates strong promoter confidence, with a consistently high promoter holding around 71% from June 2022 to March 2025. There has been a decreasing trend in FII holdings, dropping from 7.22% in June 2022 to 2.44% in March 2025. Conversely, DII holdings have increased from 4.55% in June 2022 to 12.48% in March 2025. Public shareholding has remained relatively stable, fluctuating between 16.81% and 12.84%.

There is no specific data available on off-balance sheet exposures. Therefore, it is challenging to quantify the potential risks associated with such exposures.

There is no specific data available on contingent liabilities. Therefore, a comprehensive evaluation of potential contingent liabilities is not possible with the given data.

There is no specific data available indicating accounting quality red flags.

There is no specific data available on segment performance volatility. Therefore, it is not possible to assess the stability and consistency of performance across different segments of the company.

There is no specific data available on foreign exchange or interest rate exposure. Therefore, the potential risks from currency fluctuations or interest rate changes cannot be determined.

There is no specific data available on regulatory compliance cost trends. Therefore, it is not possible to evaluate the increasing or decreasing trends of these costs and their impact on the company's financials.